drugset
drugset / Trial / NCT00004258

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

NCT00004258 ↗

Phase 1 Completed 40 enrolled Indiana University National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of EMD 121974 in treating patients who have locally advanced or metastatic cancer.

Timeline

Start
1999-12
Primary completion
2001-08
Completion
2001-09

Drugs

EvaluationDrugModalityDoseRoute
Subject cilengitide Peptide — Intravenous

Indications

cancer of unknown primary site leukemia myelodysplastic syndrome myeloproliferative neoplasm plasma cell neoplasm precancerous condition small intestine cancer